L2L Microarray Analysis Tool
Results for N06AA.profile.ud50
| Results summary | View all lists in L2L MDB | View all genes in N06AA.profile.ud50 |
| List Name | Description | Total probes |
Expected matches |
Actual matches |
Fold Enrichment |
Binomial p-value |
|---|---|---|---|---|---|---|
| il2_pbmc_48hr_up | Up-regulated at 48 hr following treatment of peripheral blood mononuclear cells (PBMC) with recombinant IL-2. | 511 | 2.53 | 19 | 7.52 | 2.58e-11 |
| serum_fibroblast_core_dn | Core group of genes consistently down-regulated following exposure to serum in a variety of human fibroblast cell lines (higher expression in quiescent cells, not cell-cycle dependent) | 319 | 1.58 | 15 | 9.51 | 1.24e-10 |
| cpr_low_liver_up | Up-regulated in mouse liver tissue from mice with reduced liver expression of NADPH-cytochrome P450 reductase (CPR), versus normal controls | 32 | 0.16 | 7 | 44.25 | 2.18e-10 |
| adipogenesis_hmsc_class3_up | Up-regulated 3-14 days following the differentiation of human bone marrow mesenchymal stem cells (hMSC) into adipocytes, versus untreated hMSC cells (Class III) | 109 | 0.54 | 10 | 18.56 | 2.38e-10 |
| il2_pbmc_6hr_up | Up-regulated at 6hr following treatment of peripheral blood mononuclear cells (PBMC) with recombinant IL-2. | 530 | 2.62 | 18 | 6.87 | 3.61e-10 |
| cpr_null_liver_up | Up-regulated in mouse liver tissue from mice in which NADPH-cytochrome P450 reductase (CPR) was specifically deleted in the liver by cre-lox recombination, versus lox-only controls | 64 | 0.32 | 8 | 25.28 | 1.23e-09 |
| il2_pbmc_24hr_dn | Down-regulated at 24 hr following treatment of peripheral blood mononuclear cells (PBMC) with recombinant IL-2. | 646 | 3.19 | 19 | 5.95 | 1.27e-09 |
| bay_pbmc_24hr_up | Up-regulated at 24 hr following treatment of peripheral blood mononuclear cells (PBMC) with BAY 50-4798, an IL-2 receptor agonist. | 202 | 1.00 | 9 | 9.01 | 9.65e-07 |
| bay_pbmc_6hr_up | Up-regulated at 6 hr following treatment of peripheral blood mononuclear cells (PBMC) with BAY 50-4798, an IL-2 receptor agonist. | 475 | 2.35 | 13 | 5.54 | 1.09e-06 |
| idx_tsa_dn_cluster4 | Strongly down-regulated at 8-48 hours during differentiation of 3T3-L1 fibroblasts into adipocytes with IDX (insulin, dexamethasone and isobutylxanthine), vs. fibroblasts treated with IDX + TSA to prevent differentiation (cluster 4) | 46 | 0.23 | 5 | 21.99 | 3.42e-06 |
| as3_hek293_dn | Downregulated in HEK293 cells by treatment with arsenite | 12 | 0.06 | 3 | 50.57 | 2.57e-05 |
| hypoxia_fibro_young_up | Upregulated by hypoxia in normal fibroblasts from young, but not old, donors (Table 1) | 15 | 0.07 | 3 | 40.45 | 5.26e-05 |
| alk5_hmvec_2hr_up | Up-regulated 2 hr following constitutive activation of TGFbeta receptor ALK5,, which activates the Smad2/3 pathway, in human microvessel endothelial cells (HMVEC). | 347 | 1.72 | 9 | 5.25 | 7.16e-05 |
| alk5_hmvec_4hr_up | Up-regulated 4 hr following constitutive activation of TGFbeta receptor ALK5,, which activates the Smad2/3 pathway, in human microvessel endothelial cells (HMVEC). | 347 | 1.72 | 9 | 5.25 | 7.16e-05 |
| hypoxia_normal_up | Upregulated by hypoxia in normal, RPTEC renal cells (Fig. 3) | 376 | 1.86 | 9 | 4.84 | 1.31e-04 |
| irs1_ko_adip_up | Up-regulated in brown preadipocytes from Irs1-knockout mice, which display severe defects in adipocyte differentiation, versus wild-type controls | 159 | 0.79 | 6 | 7.63 | 1.56e-04 |
| bay_pbmc_48hr_up | Up-regulated at 48 hr following treatment of peripheral blood mononuclear cells (PBMC) with BAY 50-4798, an IL-2 receptor agonist. | 475 | 2.35 | 10 | 4.26 | 1.61e-04 |
| alk1_hmvec_2hr_up | Up-regulated 2 hr following constitutive activation of TGFbeta receptor ALK1, which activates the Smad1/5 pathway, in human microvessel endothelial cells (HMVEC). | 593 | 2.93 | 11 | 3.75 | 2.29e-04 |
| alk1_hmvec_4hr_up | Up-regulated 4 hr following constitutive activation of TGFbeta receptor ALK1, which activates the Smad1/5 pathway, in human microvessel endothelial cells (HMVEC). | 593 | 2.93 | 11 | 3.75 | 2.29e-04 |
| insulin_adip_insens_dn | Down-regulated by insulin in murine adipocytes, and continue to respond following induction of insulin-resistance with TNFalpha treatment | 25 | 0.12 | 3 | 24.27 | 2.56e-04 |
| senescence_hela_dn | Down-regulated in HeLa/HPV16E6 cells 6 days following induction of senescence by repression of HPV E7 via HPV E2 and subsequent reactivation of Rb. | 341 | 1.69 | 8 | 4.75 | 3.49e-04 |
| fsh_ovary_mcv152_up | Up-regulated in ovarian epithelial cells (MCV152) 72 hours following FSH treatment, compared to untreated | 120 | 0.59 | 5 | 8.43 | 3.51e-04 |
| hdaci_colon_tsa_up | Upregulated by TSA at any timepoint up to 48 hrs in SW260 colon carcinoma cells | 122 | 0.60 | 5 | 8.29 | 3.79e-04 |
| insulin_adip_sens_dn | Down-regulated by insulin in murine adipocytes, but response is blunted following induction of insulin-resistance with TNFalpha treatment | 29 | 0.14 | 3 | 20.92 | 4.01e-04 |
| idx_tsa_up_cluster3 | Strongly up-regulated at 16-24 hours during differentiation of 3T3-L1 fibroblasts into adipocytes with IDX (insulin, dexamethasone and isobutylxanthine), vs. fibroblasts treated with IDX + TSA to prevent differentiation (cluster 3) | 136 | 0.67 | 5 | 7.44 | 6.22e-04 |
| calres_presenillin_ko_hippocampus_up | Up-regulated by calorie restriction in the hippocampus of 8 month-old presenillin-1 and -2 conditional double knock-out mice, compared to normal-diet controls. | 137 | 0.68 | 5 | 7.38 | 6.43e-04 |
| uvc_high_all_up | Up-regulated at any timepoint following treatment of WS1 human skin fibroblasts with UVC at a high dose (50 J/m^2) (clusters b1-b4) | 34 | 0.17 | 3 | 17.85 | 6.45e-04 |
| hdaci_colon_tsabut_up | Upregulated by both butyrate and TSA at any timepoint up to 48 hrs in SW260 colon carcinoma cells | 79 | 0.39 | 4 | 10.24 | 6.68e-04 |
| aged_mouse_retina_any_up | Up-regulated in the retina of 16-month aged mice from any of four strains (S8, S10, SR1, B6J), versus 3-month young controls | 36 | 0.18 | 3 | 16.86 | 7.64e-04 |
| senescence_hff_dn | Down-regulated in primary human foreskin fibroblasts at replicative senescence (passage 26) compared to active replication (passage 8). | 299 | 1.48 | 7 | 4.74 | 8.15e-04 |
| rb_ko_up | Up-regulated in MEFs derived from Rb knock-out mice, versus wild-type controls. | 155 | 0.77 | 5 | 6.52 | 1.12e-03 |
| cmv_hcmv_timecourse_16hrs_up | Up-regulated in fibroblasts following infection with human cytomegalovirus (at least 3-fold, with Affymetrix change call, in at least two consectutive timepoints), with maximum change at 16 hours | 93 | 0.46 | 4 | 8.70 | 1.23e-03 |
| hdaci_colon_tsa48hrs_dn | Downregulated by TSA at 48 hrs in SW260 colon carcinoma cells | 11 | 0.05 | 2 | 36.78 | 1.31e-03 |
| hdaci_colon_but24hrs_up | Upregulated by butyrate at 24 hrs in SW260 colon carcinoma cells | 95 | 0.47 | 4 | 8.52 | 1.33e-03 |
| et743_hela_up | Upregulated by Et-743 in HeLa cells | 99 | 0.49 | 4 | 8.17 | 1.55e-03 |
| senescence_rep-ind_dn | Down-regulated in models of both replicative (high-passge human foreskin fibroblast) and induced (repression of E7 in HeLa) cellular senescence. | 171 | 0.85 | 5 | 5.91 | 1.72e-03 |
| bay_pbmc_4hr_up | Up-regulated at 4 hr following treatment of peripheral blood mononuclear cells (PBMC) with BAY 50-4798, an IL-2 receptor agonist. | 544 | 2.69 | 9 | 3.35 | 1.80e-03 |
| p53_brca1_up | Upregulated by expression of p53 in p53-null, brca1-null MEFs; most genes are further upregulated by simultaneous expression of BRCA1 | 49 | 0.24 | 3 | 12.38 | 1.88e-03 |
| bcnu_glioma_nomgmt_48hrs_dn | Down-regulated in an MGMT-deficient glioma cell line (A172) at 48 hours following treatment with BCNU | 50 | 0.25 | 3 | 12.14 | 1.99e-03 |
| p21_any_dn | Down-regulated at any timepoint (4-24 hrs) follwing ectopic expression of p21 (CDKN1A) in OvCa cells | 50 | 0.25 | 3 | 12.14 | 1.99e-03 |
| stemcell_neural_up | Enriched in mouse neural stem cells, compared to differentiated brain and bone marrow cells | 2805 | 13.87 | 26 | 1.87 | 2.25e-03 |
| uvc_high_b2_up | Up-regulated at 18-24 hours following treatment of WS1 human skin fibroblasts with UVC at a high dose (50 J/m^2) (cluster b2) | 15 | 0.07 | 2 | 26.97 | 2.46e-03 |
| et743_sarcoma_24hrs_up | Up-regulated at 24 hours following treatment with Et-743 in at least 8 of 11 sarcoma cell lines | 16 | 0.08 | 2 | 25.28 | 2.80e-03 |
| hsc_mature_fetal | Up-regulated in mouse mature bood cells from fetal liver, compared to hematopoietic progenitors (Mature Blood Cells Shared + Fetal) | 376 | 1.86 | 7 | 3.77 | 2.97e-03 |
| tgfb_hmvec_4hr_dn | Down-regulated 4 hr following treatment of human microvessel endothelial cells (HMVEC) with TGFbeta. | 1321 | 6.53 | 15 | 2.30 | 3.01e-03 |
| bleo_mouse_lymph_high_4hrs_up | Up-regulated at 4 hours following treatment of mouse lymphocytes (TK 3.7.2C) with a high dose of bleomycin | 17 | 0.08 | 2 | 23.80 | 3.16e-03 |
| hdaci_colon_tsa2hrs_up | Upregulated by TSA at 2 hrs in SW260 colon carcinoma cells | 61 | 0.30 | 3 | 9.95 | 3.51e-03 |
| bay_pbmc_2hr_up | Up-regulated at 2 hr following treatment of peripheral blood mononuclear cells (PBMC) with BAY 50-4798, an IL-2 receptor agonist. | 606 | 3.00 | 9 | 3.00 | 3.67e-03 |
| 5azac-tsa_hepg2_dn | Down-regulated in human hepatoma cells (HepG2) following 24 hrs treatment with 2.5 microM 5-aza-2-deoxycytidine (5azaC) and 24 hrs treatment with both 5azaC and 500 nM trichostatin A (TSA). | 2343 | 11.58 | 22 | 1.90 | 4.00e-03 |
| tsa_hepg2_dn | Down-regulated in human hepatoma cells (HepG2) following 24 hrs treatment with 500 nM trichostatin A (TSA). | 1237 | 6.12 | 14 | 2.29 | 4.17e-03 |
| il2_pbmc_4hr_up | Up-regulated at 4 hr following treatment of peripheral blood mononuclear cells (PBMC) with recombinant IL-2. | 510 | 2.52 | 8 | 3.17 | 4.35e-03 |
| il2_pbmc_2hr_up | Up-regulated at 2 hr following treatment of peripheral blood mononuclear cells (PBMC) with recombinant IL-2. | 66 | 0.33 | 3 | 9.19 | 4.38e-03 |
| il2_pbmc_30min_up | Up-regulated at 30 min following treatment of peripheral blood mononuclear cells (PBMC) with recombinant IL-2. | 66 | 0.33 | 3 | 9.19 | 4.38e-03 |
| nf90_dn | Downregulated by ectopic expression of NF90 in GHOST(3)CXCR4 cells | 66 | 0.33 | 3 | 9.19 | 4.38e-03 |
| heatshock_hela_4hr_dn | Down-regulated at 4 hours following 1.5 hr 43degC heat shock of HeLa cells compared to untreated controls (> 1.5-fold, FDR < 0.05). | 1829 | 9.04 | 18 | 1.99 | 5.45e-03 |
| cisplatin_probcell_up | Up-regulated in pro-B cells (FL5.12) following treatment with cisplatin | 23 | 0.11 | 2 | 17.59 | 5.77e-03 |
| cmv_hcmv_timecourse_all_up | Up-regulated in fibroblasts following infection with human cytomegalovirus (at least 3-fold, with Affymetrix change call, in at least two consectutive timepoints) | 895 | 4.42 | 11 | 2.49 | 5.79e-03 |
| hdaci_colon_cur24hrs_up | Upregulated by curcumin at 24 hrs in SW260 colon carcinoma cells | 73 | 0.36 | 3 | 8.31 | 5.81e-03 |
| stemcell_embryonic_up | Enriched in mouse embryonic stem cells, compared to differentiated brain and bone marrow cells | 1989 | 9.83 | 19 | 1.93 | 5.96e-03 |
| scw_joint_react_dn | Down-regulated in rat ankle joints 16 days after intra-articular injection of Streptococcal cell wall (SCW), and 3 days after systemic injection of SCW to reactivate joint inflammation. | 231 | 1.14 | 5 | 4.38 | 6.18e-03 |
| cancerdrugs_probcell_up | Up-regulated by at least two of four cancer drugs (cisplatin, camptothecin, methotrextate and/or paclitaxel) in pro-B cells (FL5.12) | 24 | 0.12 | 2 | 16.86 | 6.28e-03 |
| methotrexate_probcell_up | Up-regulated in pro-B cells (FL5.12) following treatment with methotrexate | 24 | 0.12 | 2 | 16.86 | 6.28e-03 |
| idx_tsa_up_cluster5 | Up-regulated at 48-96 hours during differentiation of 3T3-L1 fibroblasts into adipocytes with IDX (insulin, dexamethasone and isobutylxanthine), vs. fibroblasts treated with IDX + TSA to prevent differentiation (cluster 5) | 149 | 0.74 | 4 | 5.43 | 6.68e-03 |
| cox1_ko_hippocampus_dn | Down-regulated in the hippocampus of COX1-/- mice compared to wild-type controls. | 77 | 0.38 | 3 | 7.88 | 6.73e-03 |
| heat_glioblastoma_up | Up-regulated following 1 hr 43degC heat shock in human glioblastoma cells (U87MG). | 78 | 0.39 | 3 | 7.78 | 6.98e-03 |
| csb_reliable_dn | Down-regulated reliably by stable expression of wt CSB in hTERT-immortalized CS1AN CSB-null fibroblasts vs. eGFP-expressing controls (7 of 9 pairwise comparisons). | 558 | 2.76 | 8 | 2.90 | 7.32e-03 |
| p21_middle_dn | Down-regulated at intermediate timepoints (12-16 hrs) follwing ectopic expression of p21 (CDKN1A) in OvCa cells | 26 | 0.13 | 2 | 15.56 | 7.34e-03 |
| camptothecin_probcell_up | Up-regulated in pro-B cells (FL5.12) following treatment with camptothecin | 28 | 0.14 | 2 | 14.45 | 8.48e-03 |
| brcax_a_up | Up-regulated in one group (A) of BRCAx tumors (familial non-BRCA1/BRCA2 breast cancer), compared to a second BRCAx group (B) | 30 | 0.15 | 2 | 13.48 | 9.70e-03 |
| hypoxia_rcc_novhl_up | Upregulated by hypoxia in VHL-null renal carcinoma cells (Fig. 4h+i) | 88 | 0.44 | 3 | 6.90 | 9.70e-03 |